share_log

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

S-1/A：证券上市注册声明(修正)
美股SEC公告 ·  09/12 17:14

Moomoo AI 已提取核心信息

180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp. has announced an offering of up to 3,296,703 shares of common stock, pre-funded warrants to purchase an equivalent number of shares, and common warrants to purchase up to the same number of shares. The pre-funded warrants have an exercise price of $0.0001 per share and are immediately exercisable. The common warrants have an assumed initial exercise price of $1.82 per share, equal to the last reported sales price of the company's common stock on Nasdaq as of September 10, 2024. These common warrants will be exercisable upon obtaining stockholder approval or immediately if certain pricing conditions are met. The offering is being conducted on a 'reasonable best efforts' basis by A.G.P./Alliance Global Partners as the sole placement agent. The company intends to use the net proceeds for research and development expenses, transaction costs to complete a strategic transaction, legal expenses, and working capital. The offering is expected to close on or about the date of the prospectus, subject to customary closing conditions.
180 Life Sciences Corp.宣布发行高达3,296,703股普通股，预先资助的认股权证以购买相同数量的股票，以及购买相同数量股票的普通认股权证。预先资助的认股权证的行使价格为每股0.0001美元，并可立即行使。普通认股权证的假定初始行使价格为每股1.82美元，等于2024年9月10日纳斯达克公司普通股的最后报告销售价格。这些普通认股权证将在获得股东批准后行使，或者在满足某些定价条件时立即行使。这项发行由A.G.P./Alliance Global Partners作为唯一的配售代理商进行，并采用"合理尽力"的方式进行。公司打算将净收益用于研发费用、完成战略交易的交易成本、法律费用和营运资金。预计本次发行将于招股说明书日期或约定的日期结束，视习惯的交割条件而定。
180 Life Sciences Corp.宣布发行高达3,296,703股普通股，预先资助的认股权证以购买相同数量的股票，以及购买相同数量股票的普通认股权证。预先资助的认股权证的行使价格为每股0.0001美元，并可立即行使。普通认股权证的假定初始行使价格为每股1.82美元，等于2024年9月10日纳斯达克公司普通股的最后报告销售价格。这些普通认股权证将在获得股东批准后行使，或者在满足某些定价条件时立即行使。这项发行由A.G.P./Alliance Global Partners作为唯一的配售代理商进行，并采用"合理尽力"的方式进行。公司打算将净收益用于研发费用、完成战略交易的交易成本、法律费用和营运资金。预计本次发行将于招股说明书日期或约定的日期结束，视习惯的交割条件而定。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间